Investor Relations > 2014 Press Releases

2014 Press Releases

Keyword Search
2015 | 2014 | 2013 | 2012 | 2011
04/17/14Akorn Completes Acquisition of Hi-Tech Pharmacal
LAKE FOREST, Ill.--(BUSINESS WIRE)--Akorn, Inc. (NASDAQ: AKRX), a niche pharmaceutical company, announced today that it has completed its previously announced acquisition of Hi-Tech Pharmacal Co., Inc. (NASDAQ: HITK) for $640 million in cash. The combination of Akorn and Hi-Tech will transform the Company into a larger, more diversified generic player. This combination also brings critical mass and scale to Akorn’s business and strengthens the Company’s position with retail and institutional cus... 
Printer Friendly Version
03/11/14Hi-Tech Pharmacal Reports Sales of $59.9 Million for the Third Quarter Ended January 31, 2014
AMITYVILLE, N.Y.--(BUSINESS WIRE)--Mar. 11, 2014-- Hi-Tech Pharmacal Co., Inc. (NASDAQ:HITK) today reported results for the third fiscal quarter ended January 31, 2014. Net sales of $59.9 million for the third quarter compared to $64.3 million for the same prior year period GAAP income of $8.4 million or $0.59 per diluted share for the third quarter Adjusted non-GAAP net income of $10.6 million or $0.75 per diluted share for the third quarter Net sales of $169.0 million for the nine mo... 
Printer Friendly Version
01/23/14Hi-Tech Pharmacal Receives Final Approval for Bromfenac Ophthalmic Solution, 0.09% (Once-A-Day)
AMITYVILLE, N.Y.--(BUSINESS WIRE)--Jan. 23, 2014-- Hi-Tech Pharmacal Co., Inc. (NASDAQ:HITK), a specialty pharmaceuticals company, announced today that the US Food and Drug Administration, (FDA) granted final approval for the Company's Abbreviated New Drug Application, (ANDA) for Bromfenac Ophthalmic Solution, 0.09% (Once-A-Day), the generic for ISTA Pharmaceuticals' Bromday ® ophthalmic solution, 0.09%. The product is used to treat postoperative inflammation and reduction of ocular pain in pati... 
Printer Friendly Version
HITK (Common Stock)
ExchangeNASDAQ GS (US Dollar)
Change (%) Stock is Down 0.01 (0.02%)
Data as of 04/16/14 4:00 p.m. ET
Refresh quote
Quotes delayed at least 15 minutes. Market data provided by Interactive Data.

Terms & Conditions. Powered and implemented by Interactive Data Managed Solutions.

Contact Information
Primary IR Contact
Anne Siebert
Phone: 631-789-8228
Ext. Ext. 4120
© Hi-Tech Pharmacal Co. Inc (a NASDAQ company)